Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation

PLoS Pathogens

Volumn 12, Issue 5, 2016, Pages

  Delviks Frankenberry, Krista A ^a   Nikolaitchik, Olga A ^a   Burdick, Ryan C ^a   Gorelick, Robert J ^b   Keele, Brandon F ^b   Hu, Wei Shau ^a   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE MUTATION; GENETIC VARIATION; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN VERSUS ANIMAL COMPARISON; MUTAGENESIS; MUTATION RATE; PROGENY; REVERSE TRANSCRIPTION; VIRION; WILD TYPE; GENETIC RECOMBINATION; GENETICS; HEK293 CELL LINE; METABOLISM; MUTATION; POLYMERASE CHAIN REACTION;

APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE;

CYTOSINE DEAMINASE; GENETIC VARIATION; HEK293 CELLS; HIV-1; HUMANS; MUTATION; MUTATION RATE; POLYMERASE CHAIN REACTION; RECOMBINATION, GENETIC;

EID: 84973340140     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005646     Document Type: Article

References (103)

1. Coffin J, Swanstrom R, HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harbor perspectives in medicine. 2013; 3(1):a012526. doi: 10.1101/cshperspect.a01252623284080
2. Mansky LM, Temin HM, Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. Journal of virology. 1995; 69(8):5087–94. 7541846
3. Kim T, Mudry RA, Jr.Rexrode CA, 2ndPathak VK, Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. Journal of virology. 1996; 70(11):7594–602. 8892879
4. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH, Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. Journal of virology. 2010; 84(19):9864–78. doi: 10.1128/JVI.00915-1020660205
5. Mansky LM, Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS research and human retroviruses. 1996; 12(4):307–14. 8906991
6. Pathak VK, Temin HM, Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87(16):6019–23. 2201018
7. Ji JP, Loeb LA, Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry. 1992; 31(4):954–8. 1370910
8. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD, Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. The Journal of biological chemistry. 2002; 277(41):38053–61. 12151398
9. Thomas MJ, Platas AA, Hawley DK, Transcriptional fidelity and proofreading by RNA polymerase II. Cell. 1998; 93(4):627–37. 9604937
10. Wang D, Bushnell DA, Huang X, Westover KD, Levitt M, Kornberg RD, Structural basis of transcription: backtracked RNA polymerase II at 3.4 angstrom resolution. Science. 2009; 324(5931):1203–6. doi: 10.1126/science.116872919478184
11. de Mercoyrol L, Corda Y, Job C, Job D, Accuracy of wheat-germ RNA polymerase II. General enzymatic properties and effect of template conformational transition from right-handed B-DNA to left-handed Z-DNA. European journal of biochemistry / FEBS. 1992; 206(1):49–58. 1587282
12. Rhodes T, Wargo H, Hu WS, High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. Journal of virology. 2003; 77(20):11193–200. 14512567
13. Rhodes TD, Nikolaitchik O, Chen J, Powell D, Hu WS, Genetic recombination of human immunodeficiency virus type 1 in one round of viral replication: effects of genetic distance, target cells, accessory genes, and lack of high negative interference in crossover events. Journal of virology. 2005; 79(3):1666–77. 15650192
14. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996; 271(5255):1582–6. 8599114
15. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999; 354(9192):1782–5. 10577640
16. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F, T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nature immunology. 2000; 1(4):285–9. 11017098
17. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387(6629):183–8. 9144289
18. Sheehy AM, Gaddis NC, Choi JD, Malim MH, Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646–50. 12167863
19. Lecossier D, Bouchonnet F, Clavel F, Hance AJ, Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 2003; 300(5622):1112. 12750511
20. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS, DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nature immunology. 2003; 4(7):641–3. 12830140
21. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6):803–9. 12809610
22. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D, Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424(6944):99–103. 12808466
23. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L, The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003; 424(6944):94–8. 12808465
24. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic acids research. 2007; 35(21):7096–108. 17942420
25. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current biology: CB. 2005; 15(2):166–70. 15668174
26. Adolph MB, Webb J, Chelico L, Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase. PloS one. 2013; 8(5):e64196. doi: 10.1371/journal.pone.006419623717565
27. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, Kleiman L, The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. Journal of virology. 2007; 81(20):11322–31. 17670826
28. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH, APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS pathogens. 2008; 4(12):e1000231. doi: 10.1371/journal.ppat.100023119057663
29. Anderson JL, Hope TJ, APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology. 2008; 375(1):1–12. doi: 10.1016/j.virol.2008.01.04218308358
30. Li XY, Guo F, Zhang L, Kleiman L, Cen S, APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. The Journal of biological chemistry. 2007; 282(44):32065–74. 17855362
31. Holmes RK, Koning FA, Bishop KN, Malim MH, APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. The Journal of biological chemistry. 2007; 282(4):2587–95. 17121840
32. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of virology. 2007; 81(13):7099–110. 17428871
33. Mitra M, Singer D, Mano Y, Hritz J, Nam G, Gorelick RJ, et al. Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities. Retrovirology. 2015; 12:3. doi: 10.1186/s12977-014-0130-825614027
34. Mbisa JL, Bu W, Pathak VK, APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. Journal of virology. 2010; 84(10):5250–9. doi: 10.1128/JVI.02358-0920219927
35. Conticello SG, Harris RS, Neuberger MS, The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current biology: CB. 2003; 13(22):2009–13. 14614829
36. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T, Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. The Journal of biological chemistry. 2005; 280(19):18573–8. 15781449
37. Marin M, Rose KM, Kozak SL, Kabat D, HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature medicine. 2003; 9(11):1398–403. 14528301
38. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D, Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. The Journal of biological chemistry. 2004; 279(9):7792–8. 14672928
39. Stopak K, de Noronha C, Yonemoto W, Greene WC, HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular cell. 2003; 12(3):591–601. 14527406
40. Sheehy AM, Gaddis NC, Malim MH, The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature medicine. 2003; 9(11):1404–7. 14528300
41. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003; 302(5647):1056–60. 14564014
42. Janini M, Rogers M, Birx DR, McCutchan FE, Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. Journal of virology. 2001; 75(17):7973–86. 11483742
43. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. Journal of virology. 2008; 82(6):3125–30. 18077705
44. Neogi U, Shet A, Sahoo PN, Bontell I, Ekstrand ML, Banerjea AC, et al. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals. Journal of the International AIDS Society. 2013; 16:18472. doi: 10.7448/IAS.16.1.1847223443042
45. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF, G—>A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. Journal of virology. 2005; 79(3):1975–80. 15650227
46. Koulinska IN, Chaplin B, Mwakagile D, Essex M, Renjifo B, Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS research and human retroviruses. 2003; 19(12):1115–23. 14709248
47. Chelico L, Pham P, Calabrese P, Goodman MF, APOBEC3G DNA deaminase acts processively 3' —> 5' on single-stranded DNA. Nature structural & molecular biology. 2006; 13(5):392–9.
48. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH, Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current biology: CB. 2004; 14(15):1392–6. 15296758
49. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature structural & molecular biology. 2004; 11(5):435–42.
50. Hache G, Liddament MT, Harris RS, The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. The Journal of biological chemistry. 2005; 280(12):10920–4. 15647250
51. Holtz CM, Sadler HA, Mansky LM, APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. Nucleic acids research. 2013; 41(12):6139–48. doi: 10.1093/nar/gkt24623620282
52. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS, Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. Journal of molecular biology. 2004; 337(3):585–96. 15019779
53. Liddament MT, Brown WL, Schumacher AJ, Harris RS, APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current biology: CB. 2004; 14(15):1385–91. 15296757
54. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR, A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. The EMBO journal. 2004; 23(12):2451–8. 15152192
55. Pathak VK, Temin HM, Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87(16):6024–8. 2166940
56. Parthasarathi S, Varela-Echavarria A, Ron Y, Preston BD, Dougherty JP, Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implications. Journal of virology. 1995; 69(12):7991–8000. 7494312
57. Julias JG, Kim T, Arnold G, Pathak VK, The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate. Journal of virology. 1997; 71(6):4254–63. 9151812
58. Sadler HA, Stenglein MD, Harris RS, Mansky LM, APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. Journal of virology. 2010; 84(14):7396–404. doi: 10.1128/JVI.00056-1020463080
59. Hache G, Mansky LM, Harris RS, Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS reviews. 2006; 8(3):148–57. 17078485
60. Jern P, Russell RA, Pathak VK, Coffin JM, Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS pathogens. 2009; 5(4):e1000367. doi: 10.1371/journal.ppat.100036719343218
61. Deforche K, Camacho R, Laethem KV, Shapiro B, Moreau Y, Rambaut A, et al. Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. Journal of computational biology: a journal of computational molecular cell biology. 2007; 14(8):1105–14.
62. Ebrahimi D, Anwar F, Davenport MP, APOBEC3 has not left an evolutionary footprint on the HIV-1 genome. Journal of virology. 2011; 85(17):9139–46. doi: 10.1128/JVI.00658-1121697498
63. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS pathogens. 2009; 5(5):e1000414. doi: 10.1371/journal.ppat.100041419424423
64. Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, Welch JJ, et al. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS genetics. 2012; 8(3):e1002550. doi: 10.1371/journal.pgen.100255022457633
65. Mulder LC, Harari A, Simon V, Cytidine deamination induced HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(14):5501–6. doi: 10.1073/pnas.071019010518391217
66. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. Journal of virology. 2010; 84(19):10402–5. doi: 10.1128/JVI.01223-1020660203
67. McCallum M, Oliveira M, Ibanescu RI, Kramer VG, Moisi D, Asahchop EL, et al. Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase. Antimicrobial agents and chemotherapy. 2013; 57(10):4681–8. doi: 10.1128/AAC.01029-1323856772
68. Russell RA, Moore MD, Hu WS, Pathak VK, APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology. 2009; 6:16. doi: 10.1186/1742-4690-6-1619216784
69. Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM, Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology. 2013; 443(2):306–12. doi: 10.1016/j.virol.2013.05.01923791226
70. Freed EO, Englund G, Martin MA, Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. Journal of virology. 1995; 69(6):3949–54. 7745752
71. Chen J, Nikolaitchik O, Singh J, Wright A, Bencsics CE, Coffin JM, et al. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(32):13535–40. doi: 10.1073/pnas.090682210619628694
72. Nikolaitchik OA, Dilley KA, Fu W, Gorelick RJ, Tai SH, Soheilian F, et al. Dimeric RNA recognition regulates HIV-1 genome packaging. PLoS pathogens. 2013; 9(3):e1003249. doi: 10.1371/journal.ppat.100324923555259
73. Moore MD, Fu W, Nikolaitchik O, Chen J, Ptak RG, Hu WS, Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. Journal of virology. 2007; 81(8):4002–11. 17267488
74. Coffin JM, Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. The Journal of general virology. 1979; 42(1):1–26. 215703
75. Hu WS, Temin HM, Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87(4):1556–60. 2304918
76. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. Journal of virology. 2008; 82(16):8172–82. doi: 10.1128/JVI.01115-0818550667
77. Kourteva Y, De Pasquale M, Allos T, McMunn C, D'Aquila RT, APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology. 2012; 430(1):1–9. doi: 10.1016/j.virol.2012.03.01822579353
78. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013; 155(3):540–51. doi: 10.1016/j.cell.2013.09.02024243014
79. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S, Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic acids research. 2006; 34(17):4677–84. 16963778
80. Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, Hance AJ, et al. Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. Journal of virology. 2006; 80(7):3679–83. 16537639
81. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, Robb ML, et al. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology. 2008; 376(1):101–11. doi: 10.1016/j.virol.2008.03.01718436274
82. Nikolaitchik OA, Galli A, Moore MD, Pathak VK, Hu WS, Multiple barriers to recombination between divergent HIV-1 variants revealed by a dual-marker recombination assay. Journal of molecular biology. 2011; 407(4):521–31. doi: 10.1016/j.jmb.2011.01.05221295586
83. Motomura K, Chen J, Hu WS, Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses. Journal of virology. 2008; 82(4):1923–33. 18057256
84. Chin MP, Chen J, Nikolaitchik OA, Hu WS, Molecular determinants of HIV-1 intersubtype recombination potential. Virology. 2007; 363(2):437–46. 17336363
85. Chin MP, Lee SK, Chen J, Nikolaitchik OA, Powell DA, Fivash MJ, Jr.et al. Long-range recombination gradient between HIV-1 subtypes B and C variants caused by sequence differences in the dimerization initiation signal region. Journal of molecular biology. 2008; 377(5):1324–33. doi: 10.1016/j.jmb.2008.02.00318314135
86. Galli A, Kearney M, Nikolaitchik OA, Yu S, Chin MP, Maldarelli F, et al. Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication. Journal of virology. 2010; 84(15):7651–61. doi: 10.1128/JVI.00276-1020504919
87. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, et al. Recombination: Multiply infected spleen cells in HIV patients. Nature. 2002; 418(6894):144. 12110879
88. Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J, Ambrozak D, et al. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS pathogens. 2013; 9(6):e1003432. doi: 10.1371/journal.ppat.100343223818847
89. Bandyopadhyay PK, Watanabe S, Temin HM, Recombination of transfected DNAs in vertebrate cells in culture. Proceedings of the National Academy of Sciences of the United States of America. 1984; 81(11):3476–80. 6587362
90. Miller CK, Temin HM, High-efficiency ligation and recombination of DNA fragments by vertebrate cells. Science. 1983; 220(4597):606–9. 6301012
91. Cuevas JM, Geller R, Garijo R, Lopez-Aldeguer J, Sanjuan R, Extremely High Mutation Rate of HIV-1 In Vivo. PLoS biology. 2015; 13(9):e1002251. doi: 10.1371/journal.pbio.100225126375597
92. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD, Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS pathogens. 2005; 1(1):e6. 16201018
93. Kim EY, Lorenzo-Redondo R, Little SJ, Chung YS, Phalora PK, Maljkovic Berry I, et al. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS pathogens. 2014; 10(7):e1004281. doi: 10.1371/journal.ppat.100428125080100
94. Armitage AE, Deforche K, Welch JJ, Van Laethem K, Camacho R, Rambaut A, et al. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections. Journal of virology. 2014; 88(21):12882–94. doi: 10.1128/JVI.01460-1425165112
95. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, Sayon S, et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids. 2010; 24(15):2313–21. doi: 10.1097/QAD.0b013e32833e515a20729708
96. Fourati S, Lambert-Niclot S, Soulie C, Wirden M, Malet I, Valantin MA, et al. Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. Aids. 2014; 28(4):487–91. doi: 10.1097/QAD.000000000000018224401644
97. Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, et al. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015.
98. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, et al. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. Journal of virology. 2008; 82(17):8743–61. doi: 10.1128/JVI.00584-0818562517
99. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T, A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(20):9564–8. 7937806
100. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA, A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. Journal of virology. 2000; 74(10):4839–52. 10775623
101. Wu L, Martin TD, Vazeux R, Unutmaz D, KewalRamani VN, Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission. Journal of virology. 2002; 76(12):5905–14. 12021323
102. Rose PP, Korber BT, Detecting hypermutations in viral sequences with an emphasis on G—> A hypermutation. Bioinformatics. 2000; 16(4):400–1. 10869039
103. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(21):7552–7. doi: 10.1073/pnas.080220310518490657